Global Oncology Clinical Trial Monitor Market Size, Trends and Growth Opportunity, By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional, Observational, Expanded Access), By Cancer Type (Lung Cancer, Breast Cancer, Leukemia, Prostate Cancer, Others), By Region and forecast till 2030.
Global Oncology Clinical Trial Monitor Market
Global Oncology Clinical Trial Monitor Market was valued at USD 12.75 million in 2022 and is slated to reach USD 19.7 million by 2030 at a CAGR of 5.55% from 2023-2030.
Oncology clinical trials are tests carried out as part of clinical research that adhere to a set procedure. These tests are mostly carried out to gather information about the efficacy and safety of the most recent drugs. For a medicine to be approved and introduced to the market, clinical trial data is necessary. These trials are carried out in various phases, each of which depends on a particular set of variables.
Market Drivers
The market has grown as a result of increased collaboration among numerous market participants. For instance, in order to expand the use of real-world evidence and improve clinical research in oncology in 2019, IQVIA announced its partnership with Cancer Researchers. Additionally, SynexusPlus was introduced in 2018 by Acurian and Synexus, a division of PPD. A website solution for patient enrollment in various clinical studies is called SynexusPlus. It is anticipated that this programme will increase clinical trial productivity. This is anticipated to have a favourable effect on market expansion. Phase II studies are becoming more prevalent, which fuels the expansion of the market. In addition, oncology clinical trials have had a 22% increase in overall productivity since 2010 when success rates were measured relative to trial effort. Additionally, according to the Medicines Healthcare Products Regulatory Agency (MHRA), the number of applications for phase II and phase III trials increased by 5.5% between 2011 and 2016. This element therefore contributes to the market's quick growth.
Market Restraints
Oncology studies are continually evolving and emerging. As a result, few people outside of specialists are fully informed about how the trials are actually processed. Since they involve such a delicate process and the potential for many complications, these procedures demand the highest level of professionalism. This causes a market barrier as a result.
Impact of COVID-19
The COVID-19 virus has caused numerous clinical trials to be postponed or suspended. The number of trials that need to be monitored has decreased as a result, which has had an effect on the demand for clinical trial monitors. There has been a shift towards virtual monitoring of clinical trials due to limits on travel and in-person interactions. The need for technologies that enable remote data gathering and processing as well as remote monitoring solutions has increased as a result. The possibility of contracting an illness prevents many patients from travelling to medical institutions. The need for home healthcare services, including clinical trials conducted at home, has increased as a result. The demand for monitors who can remotely watch these trials and make sure they are carried out in accordance with regulatory criteria is consequently rising. Global supply chains have been interrupted by the COVID-19 pandemic, which has an effect on the availability of the tools and materials needed for clinical trial monitoring. New trial launches have been delayed as a result, and monitoring costs have gone up.
Market Segmentation
Global Oncology Clinical Trial Monitor Market is segmented into Phase, Study Design, and Cancer Type. By Phase such as Phase I, Phase II, Phase III, Phase IV. By Study Design such as Interventional, Observational, Expanded Access. By Cancer Type such as Lung Cancer, Breast Cancer, Leukemia, Prostate Cancer, Others.
Regional Analysis
Global Oncology Clinical Trial Monitor Market is segmented into five regions Americas, Europe, Asia-Pacific, and the Middle East & Africa. The cancer clinical trial monitor market is dominated by North America due to increased research and development. Government backing and the expanding use of contemporary technology in clinical research will also help the market expand in the region over the course of the forecast period. Asia-Pacific is anticipated to have significant expansion as a result of the region's increased accessibility to a sizable patient population that makes it simple to find candidates. In the next years, it is also anticipated that the region's market will rise faster due to the rising number of active investigators.
Key Players
This report includes a list of numerous Key Players, namely IQVIA Inc (U.S.)., Charles River Laboratories (U.S)., ICON Plc (Ireland), Parexel International Corporation (U.S), WuXi AppTec (China), Syneos Health (U.S)., Labcorp Drug Development (U.S.)., Parexel International Corporation (U.S.), PPD Inc. (U.S)., Medpace, Inc. (U.S.).
Market Taxonomy
By Phase
• Phase I
• Phase II
• Phase III
• Phase IV
By Study Design
• Interventional
• Observational
• Expanded Access
By Cancer Type
• Lung Cancer
• Breast Cancer
• Leukemia
• Prostate Cancer
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Latin America
o Brazil
o Argentina
o Colombia
o Peru
o Chile
o Venezuela
o Rest of Latin America
• Europe
o Germany
o France
o UK
o Russia
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o New Zealand
o Singapore
o Malaysia
o Rest of Asia Pacific
• Middle East & Africa
o Saudi Arabia
o UAE
o Egypt
o Kuwait
o South Africa
o Rest Middle East & Africa
Global Oncology Clinical Trial Monitor Market
1 Introduction
1.1 Objective of the Study
1.2 Market definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Global Oncology Clinical Trial Monitor Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Cumulative Impact due to recent Energy Crisis
4.2.5 Cumulative Impact due to nearing Economic Downturn
4.2.6 Post Covid-19 World Supply and Demand Conditions
4.2.7 Cumulative Impact of Russia-Ukraine Conflict
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global Oncology Clinical Trial Monitor Market, By Phase
5.1 Y-o-Y Growth Comparison, By Phase
5.2 Global Oncology Clinical Trial Monitor Market Share Analysis, By Phase
5.3 Global Oncology Clinical Trial Monitor Market Size and Forecast, By Phase
5.3.1 Phase I
5.3.2 Phase II
5.3.3 Phase III
5.3.4 Phase IV
6 Global Oncology Clinical Trial Monitor Market, By Study Design
6.1 Y-o-Y Growth Comparison, By Study Design
6.2 Global Oncology Clinical Trial Monitor Market Share Analysis, By Study Design
6.3 Global Oncology Clinical Trial Monitor Market Size and Forecast, By Study Design
6.3.1 Interventional
6.3.2 Observational
6.3.3 Expanded Access
7 Global Oncology Clinical Trial Monitor Market, By Cancer Type
7.1 Y-o-Y Growth Comparison, By Cancer Type
7.2 Global Oncology Clinical Trial Monitor Market Share Analysis, By Cancer Type
7.3 Global Oncology Clinical Trial Monitor Market Size and Forecast, By Cancer Type
7.3.1 Lung Cancer
7.3.2 Breast Cancer
7.3.3 Leukemia
7.3.4 Prostate Cancer
7.3.5 Others
8 Global Oncology Clinical Trial Monitor Market, By Region
8.1 Global Oncology Clinical Trial Monitor Market Share Analysis, By Region
8.2 Global Oncology Clinical Trial Monitor Market Share Analysis, By Region
8.3 Global Oncology Clinical Trial Monitor Market Size and Forecast, By Region
9 North America Oncology Clinical Trial Monitor Market Analysis and Forecast (2023-2030)
9.1 Introduction
9.2 North America Oncology Clinical Trial Monitor Market Share Analysis, By Phase
9.3 North America Oncology Clinical Trial Monitor Market Size and Forecast, By Study Design
9.4 North America Oncology Clinical Trial Monitor Market Size and Forecast, By Cancer Type
9.6 North America Oncology Clinical Trial Monitor Market Size and Forecast, By Country
9.6.1 U.S.
9.6.1.1 Market Size and Forecast, By Phase
9.6.1.2 Market Size and Forecast, By Study Design
9.6.1.3 Market Size and Forecast, By Cancer Type
9.6.2 Canada
9.6.2.1 Market Size and Forecast, By Phase
9.6.2.2 Market Size and Forecast, By Study Design
9.6.2.3 Market Size and Forecast, By Cancer Type
9.6.3 Mexico
9.6.3.1 Market Size and Forecast, By Phase
9.6.3.2 Market Size and Forecast, By Study Design
9.6.3.3 Market Size and Forecast, By Cancer Type
10 Europe Oncology Clinical Trial Monitor Market, Analysis and Forecast (2023-2030)
10.1 Introduction
10.2 Europe Oncology Clinical Trial Monitor Market Share Analysis, By Phase
10.3 Europe Oncology Clinical Trial Monitor Market Size and Forecast, By Study Design
10.4 Europe Oncology Clinical Trial Monitor Market Size and Forecast, By Cancer Type
10.5 Europe Oncology Clinical Trial Monitor Market Size and Forecast, By EV application
10.5 Europe Oncology Clinical Trial Monitor Market Size and Forecast, By Country
10.6.1 Germany
10.6.1.1 Market Size and Forecast, By Phase
10.6.1.2 Market Size and Forecast, By Study Design
10.6.1.3 Market Size and Forecast, By Cancer Type
10.6.2 France
10.6.2.1 Market Size and Forecast, By Phase
10.6.2.2 Market Size and Forecast, By Study Design
10.6.2.3 Market Size and Forecast, By Cancer Type
10.6.3 UK
10.6.3.1 Market Size and Forecast, By Phase
10.6.3.2 Market Size and Forecast, By Study Design
10.6.3.3 Market Size and Forecast, By Cancer Type
10.6.4 Russia
10.6.4.1 Market Size and Forecast, By Phase
10.6.4.2 Market Size and Forecast, By Study Design
10.6.4.3 Market Size and Forecast, By Cancer Type
10.6.5 Italy
10.6.5.1 Market Size and Forecast, By Phase
10.6.5.2 Market Size and Forecast, By Study Design
10.6.5.3 Market Size and Forecast, By Cancer Type
10.6.6 Spain
10.6.6.1 Market Size and Forecast, By Phase
10.6.6.2 Market Size and Forecast, By Study Design
10.6.6.3 Market Size and Forecast, By Cancer Type
10.6.7 Rest of Europe
10.6.7.1 Market Size and Forecast, By Phase
10.6.7.2 Market Size and Forecast, By Study Design
10.6.7.3 Market Size and Forecast, By Cancer Type
11 Asia Pacific Oncology Clinical Trial Monitor Market, Analysis and Forecast (2023-2030)
11.1 Introduction
11.2 Asia Pacific Oncology Clinical Trial Monitor Market Share Analysis, By Phase
11.3 Asia Pacific Oncology Clinical Trial Monitor Market Size and Forecast, By Study Design
11.4 Asia Pacific Oncology Clinical Trial Monitor Market Size and Forecast, By Cancer Type
11.6 Asia Pacific Oncology Clinical Trial Monitor Market Size and Forecast, By Country
11.6.1 China
11.6.1.1 Market Size and Forecast, By Phase
11.6.1.2 Market Size and Forecast, By Study Design
11.6.1.3 Market Size and Forecast, By Cancer Type
11.6.2 Japan
11.6.2.1 Market Size and Forecast, By Phase
11.6.2.2 Market Size and Forecast, By Study Design
11.6.2.3 Market Size and Forecast, By Cancer Type
11.6.3 India
11.6.3.1 Market Size and Forecast, By Phase
11.6.3.2 Market Size and Forecast, By Study Design
11.6.3.3 Market Size and Forecast, By Cancer Type
11.6.4 South Korea
11.6.3.1 Market Size and Forecast, By Phase
11.6.3.2 Market Size and Forecast, By Study Design
11.6.3.3 Market Size and Forecast, By Cancer Type
11.6.5 Australia
11.6.5.1 Market Size and Forecast, By Phase
11.6.5.2 Market Size and Forecast, By Study Design
11.6.5.3 Market Size and Forecast, By Cancer Type
11.6.6 New Zealand
11.6.5.1 Market Size and Forecast, By Phase
11.6.5.2 Market Size and Forecast, By Study Design
11.6.5.3 Market Size and Forecast, By Cancer Type
11.6.7 Singapore
11.6.7.1 Market Size and Forecast, By Phase
11.6.7.2 Market Size and Forecast, By Study Design
11.6.7.3 Market Size and Forecast, By Cancer Type
11.6.8 Malaysia
11.6.8.1 Market Size and Forecast, By Phase
11.6.8.2 Market Size and Forecast, By Study Design
11.6.8.3 Market Size and Forecast, By Cancer Type
11.6.9 Rest of Asia
11.6.9.1 Market Size and Forecast, By Phase
11.6.9.2 Market Size and Forecast, By Study Design
11.6.9.3 Market Size and Forecast, By Cancer Type
12 Latin America Oncology Clinical Trial Monitor Market, Analysis and Forecast (2023-2030)
12.1 Introduction
12.2 Latin America Oncology Clinical Trial Monitor Market Share Analysis, By Phase
12.3 Latin America Oncology Clinical Trial Monitor Market Size and Forecast, By Study Design
12.4 Latin America Oncology Clinical Trial Monitor Market Size and Forecast, By Cancer Type
12.5 Latin America Oncology Clinical Trial Monitor Market Size and Forecast, Country
12.5.1 Brazil
12.5.1.1 Market Size and Forecast, By Phase
12.5.1.2 Market Size and Forecast, By Study Design
12.5.1.3 Market Size and Forecast, By Cancer Type
12.5.2 Argentina
12.5.2.1 Market Size and Forecast, By Phase
12.5.2.2 Market Size and Forecast, By Study Design
12.5.2.3 Market Size and Forecast, By Cancer Type
12.5.3 Colombia
12.5.3.1 Market Size and Forecast, By Phase
12.5.3.2 Market Size and Forecast, By Study Design
12.5.3.3 Market Size and Forecast, By Cancer Type
12.5.4 Peru
12.5.4.1 Market Size and Forecast, By Phase
12.5.4.2 Market Size and Forecast, By Study Design
12.5.4.3 Market Size and Forecast, By Cancer Type
12.5.5 Chile
12.5.5.1 Market Size and Forecast, By Phase
12.5.5.2 Market Size and Forecast, By Study Design
12.5.5.3 Market Size and Forecast, By Cancer Type
12.5.6 Venezuela
12.5.6.1 Market Size and Forecast, By Phase
12.5.6.2 Market Size and Forecast, By Study Design
12.5.6.3 Market Size and Forecast, By Cancer Type
12.5.7 Rest of Latin America
12.5.7.1 Market Size and Forecast, By Phase
12.5.7.2 Market Size and Forecast, By Study Design
12.5.7.3 Market Size and Forecast, By Cancer Type
13 Middle East Oncology Clinical Trial Monitor Market, Analysis and Forecast (2023-2030)
13.1 Introduction
13.2 Middle East Oncology Clinical Trial Monitor Market Share Analysis, By Phase
13.3 Middle East Oncology Clinical Trial Monitor Market Size and Forecast, By Study Design
13.4 Middle East Oncology Clinical Trial Monitor Market Size and Forecast, By Cancer Type
13.5 Middle East Oncology Clinical Trial Monitor Market Size and Forecast, By Country
13.5.1 Saudi Arabia
13.5.1.1 Market Size and Forecast, By Phase
13.5.1.2 Market Size and Forecast, By Study Design
13.5.1.3 Market Size and Forecast, By Cancer Type
13.5.2 UAE
13.5.2.1 Market Size and Forecast, By Phase
13.5.2.2 Market Size and Forecast, By Study Design
13.5.2.3 Market Size and Forecast, By Cancer Type
13.5.3 Egypt
13.5.3.1 Market Size and Forecast, By Phase
13.5.3.2 Market Size and Forecast, By Study Design
13.5.3.3 Market Size and Forecast, By Cancer Type
13.5.4 Kuwait
13.5.4.1 Market Size and Forecast, By Phase
13.5.4.2 Market Size and Forecast, By Study Design
13.5.4.3 Market Size and Forecast, By Cancer Type
13.5.5 South Africa
13.5.5.1 Market Size and Forecast, By Phase
13.5.5.2 Market Size and Forecast, By Study Design
13.5.5.3 Market Size and Forecast, By Cancer Type
13.5.6 Rest of Middle East & Africa
13.5.6.1 Market Size and Forecast, By Phase
13.5.6.2 Market Size and Forecast, By Study Design
13.5.6.3 Market Size and Forecast, By Cancer Type
14 Competitive Analysis
14.1 Competition Dashboard
14.2 Market share Analysis of Top Vendors
14.3 Key Development Strategies
15 Company Profiles
15.1 IQVIA Inc (U.S.)
15.1.1 Overview
15.1.2 Offerings
15.1.3 Key Financials
15.1.4 Business Segment & Geographic Overview
15.1.5 Key Market Developments
15.1.6 Key Strategies
15.2 Charles River Laboratories (U.S)
15.2.1 Overview
15.2.2 Offerings
15.2.3 Key Financials
15.2.4 Business Segment & Geographic Overview
15.2.5 Key Market Developments
15.2.6 Key Strategies
15.3 ICON Plc (Ireland)
15.3.1 Overview
15.3.2 Offerings
15.3.3 Key Financials
15.3.4 Business Segment & Geographic Overview
15.3.5 Key Market Developments
15.3.6 Key Strategies
15.4 Parexel International Corporation (U.S)
15.4.1 Overview
15.4.2 Offerings
15.4.3 Key Financials
15.4.4 Business Segment & Geographic Overview
15.4.5 Key Market Developments
15.4.6 Key Strategies
15.5 WuXi AppTec (China)
15.5.1 Overview
15.5.2 Offerings
15.5.3 Key Financials
15.5.4 Business Segment & Geographic Overview
15.5.5 Key Market Developments
15.5.6 Key Strategies
15.6 yneos Health (U.S)
15.6.1 Overview
15.6.2 Offerings
15.6.3 Key Financials
15.6.4 Business Segment & Geographic Overview
15.6.5 Key Market Developments
15.6.6 Key Strategies
15.7 Labcorp Drug Development (U.S.)
15.7.1 Overview
15.2 Offerings
15.7.3 Key Financials
15.7.4 Business Segment & Geographic Overview
15.7.5 Key Market Developments
15.7.6 Key Strategies
15.8 Parexel International Corporation (U.S.)
15.8.1 Overview
15.8.2 Offerings
15.8.3 Key Financials
15.8.4 Business Segment & Geographic Overview
15.8.5 Key Market Developments
15.8.6 Key Strategies
15.9 PPD Inc. (U.S)
15.9.1 Overview
15.9.2 Offerings
15.9.3 Key Financials
15.9.4 Business Segment & Geographic Overview
15.9.5 Key Market Developments
15.9.6 Key Strategies
15.10 Medpace, Inc. (U.S.)
15.10.1 Overview
15.10.2 Offerings
15.10.3 Key Financials
15.10.4 Business Segment & Geographic Overview
15.10.5 Key Market Developments
15.10.6 Key Strategies
